Author: digi

Drug Utilization Studies and Physician Practice Patterns in Phase 4

June 12, 2025

Drug Utilization Studies and Physician Practice Patterns in Phase 4 Understanding Drug Utilization and Prescriber Behavior in Phase 4 Clinical Trials Introduction After regulatory approval, understanding how a medication is prescribed, dispensed, and used in the real world becomes essential. Drug Utilization Studies (DUS) conducted as part of Phase 4 clinical trials help evaluate the…

Phase 4 (Post-Marketing Surveillance)

Language Barriers and Translation in Informed Consent for Clinical Trials

June 12, 2025

digi

Language Barriers and Translation in Informed Consent for Clinical Trials Overcoming Language Barriers in Informed Consent: Translation Strategies for Clinical Trials In multinational and multilingual clinical trials, language barriers pose a significant challenge to obtaining truly informed consent. Participants must understand the study, risks, and their rights — regardless of their language. This article provides…

Informed Consent and Ethics Committees, Informed Consent Process

Using AI and Predictive Analytics for Enrollment Forecasting

June 12, 2025

digi

Using AI and Predictive Analytics for Enrollment Forecasting How AI and Predictive Analytics Are Transforming Enrollment Forecasting in Clinical Trials Accurate enrollment forecasting is one of the most critical—and difficult—tasks in clinical trial planning. Overestimates lead to delays and budget overruns, while underestimates cause unnecessary site expansion and protocol amendments. Artificial Intelligence (AI) and predictive…

Patient Recruitment and Retention, Recruitment Strategies

Common Bottlenecks in Clinical Study Start-Up and How to Avoid Them

June 12, 2025

digi

Identifying and Managing Bottlenecks in Clinical Study Start-Up Study start-up is a critical yet complex phase in clinical research. Delays in this stage can significantly impact overall study timelines, cost, and compliance. From document collection to regulatory approvals, numerous potential bottlenecks can hinder progress. In this tutorial, we explore the most common start-up bottlenecks and…

Clinical Research Operations, Study Start-Up Activities

Query Resolution Times as a Key Site Performance Indicator

June 12, 2025

digi

Using Query Resolution Times as a Site Performance Indicator in Clinical Trials In today’s highly regulated and fast-paced clinical trial landscape, the speed and accuracy with which a site resolves electronic data capture (EDC) queries has emerged as a key metric of operational excellence. Query resolution time reflects how responsive a site is to data…

Site Management and Monitoring, Site Performance Metrics

Assessing PI and Staff Availability During Feasibility in Clinical Trials

June 12, 2025

digi

How to Assess PI and Staff Availability During Clinical Trial Feasibility One of the most critical yet often overlooked components of site feasibility is evaluating the availability of the Principal Investigator (PI) and supporting staff. A well-equipped site can still underperform if key personnel are stretched thin or unavailable during critical study phases. Ensuring dedicated…

Site Feasibility Assessments, Site Management and Monitoring

Effective Communication Models and Tools Between CROs and Sponsors

June 12, 2025

digi

Effective Communication Models and Tools Between CROs and Sponsors Optimizing CRO-Sponsor Communication for Clinical Trial Success Successful collaboration between a sponsor and a Contract Research Organization (CRO) is anchored in structured, transparent, and consistent communication. With increasing trial complexity, global operations, and regulatory scrutiny, having robust communication models and digital tools is critical to ensure…

Contract Research Organizations (CROs), Full-Service CROs

Assessing PI and Staff Availability During Feasibility in Clinical Trials

June 12, 2025

digi

Assessing PI and Staff Availability During Feasibility in Clinical Trials How to Assess PI and Staff Availability During Clinical Trial Feasibility One of the most critical yet often overlooked components of site feasibility is evaluating the availability of the Principal Investigator (PI) and supporting staff. A well-equipped site can still underperform if key personnel are…

Site Feasibility Assessments, Site Management and Monitoring

Strategies for Managing High Screen Failure Rates in Phase 3 Trials: Practical Approaches to Optimize Enrollment

June 12, 2025

digi

Strategies for Managing High Screen Failure Rates in Phase 3 Trials: Practical Approaches to Optimize Enrollment How to Reduce and Manage High Screen Failure Rates in Phase 3 Clinical Trials Understanding Screen Failure in Phase 3 Trials In a clinical trial, a screen failure occurs when a potential participant undergoes screening but is found to…

Phase 3 (Confirmation and Monitoring)

Informed Consent Challenges in High-Risk Early Phase Studies

June 12, 2025

digi

Informed Consent Challenges in High-Risk Early Phase Studies Navigating Informed Consent in First-in-Human and High-Risk Clinical Trials Introduction Informed consent is a cornerstone of ethical research, but in high-risk early-phase studies—especially first-in-human (FIH) trials—the stakes are elevated. These studies involve investigational agents with no prior human exposure, uncertain pharmacology, and a real possibility of serious…

Phase 1 (Safety and Dosage)